查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1308715

2030 年酵素替代疗法 (ERT) 市场预测 - 按产品、疾病、给药途径、最终用户和地区进行的全球分析

Enzyme Replacement Therapy Market Forecasts to 2030 - Global Analysis By Product, Disease, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC 的数据，2023 年全球酵素替代疗法(ERT) 市场规模将达到101 亿美元，预测期内復合年增长率为8.6%，到□□2030 年将达到181亿美元预计达到

酵素替代疗法（ERT）用于替代遗传性酵素缺乏综合征患者缺失或缺乏的酵素。 酵素替代疗法（ERT）是向患者施用不同类型的酵素以克服酵素缺乏和相关功能障碍的过程。 罕见和慢性遗传病（例如各种类型的溶酵素体贮积病和遗传性疾病）的患病率不断增加，增加了对有效治疗方案的需求。

根据遗传和罕见疾病信息中心 (GARD) 的数据，目前美国大约有 25 至 3500 万人患有罕见疾病。

市场动态：

驱动程序

政府在医疗保健基础设施方面的支出增加

各国政府正致力于扩大医疗保健领域，以解决人们的治疗和健康问题。 随着世界各国政府和非营利组织加大力度提高公众意识，罕见病诊断率正在缓慢上升。 由于医疗保健基础设施投资增加，酵素替代疗法（ERT）市场规模预计在评估期间将会增长。

抑製剂

缺乏意识

发展中国家对酵素替代疗法 (ERT) 缺乏认识，导致其采用速度缓慢。 缺乏技术和适当的基础设施预计也会阻碍市场增长。 然而，新兴国家缺乏熟练掌握这种疗法的医疗技术人员和报销政策不足是限制市场增长的一些因素。

机会：

技术进步

生物技术的重大发展催生了日益复杂的专门酵素替代疗法 (ERT)。 重组 DNA 技术的进步导致了高质量重组酵素的生产，包括更高的稳定性、特异性和半衰期。 对基因疗法和其他尖端治疗方法的进一步研究有可能提高未来 ERT 的疗效。

威胁

昂贵的医疗费用

由于復杂的製造程序、专门的基础设施以及相对有限的患有罕见遗传性疾病的患者群体，药品价格昂贵。确实如此。 这种高昂的成本可能会给个人、医疗保健系统和保险公司带来困难。 高昂的药品成本可能导致支付或报销变得困难。 根据持续时间的不同，治疗费用也更加昂贵。

COVID-19 的影响：

COVID-19 大流行是前所未有的全球公共卫生挑战，预计将对酵素替代疗法 (ERT) 市场产生负面影响。 疫情的持续蔓延以及世界各国政府采取的措施对我们的业务产生了影响，包括未来供应链以及活性药物成分和成品的製造和运输的中断，并可能继续对我们的业务产生影响。未来，有。 再加上公共交通的中断以及对诊断行业的影响。 为了防止 COVID-19 的传播，一些非紧急的诊断程序和治疗已被暂停。

在预测期内，口腔部分预计将是最大的：

口服细分市场有望实现利润丰厚的增长，因为越来越多的患者更喜欢口服给药，因为它是一种方便且非侵入性的给药方法。 自我给药方便，患者可以在家服药，无需医疗专业人员的帮助，因此加大了研发力度，开发酵素替代疗法 (ERT) 的口服製剂以及口服特定酵素的潜力提高生物利用度和痰稳定性等优点进一步提高了全球市场中口腔细分市场的增长率。

医院领域预计在预测期内復合年增长率最高：

由于拥有先进的医疗基础设施、专业医务人员以及进行酵素替代疗法 (ERT) 的支持设施，医院部门预计在预测期内将以最快的复合年增长率增长。Masu。 医院和製药公司之间加强合作，以确保酵素替代疗法 (ERT) 的可用性和正确剂量，以及以医院为基础的临床研究和开发活动，正在推动 ERT 市场中医院细分市场的增长率进一步上升。

份额最大的地区

由于输液中心的可用性、新疗法的接受度增加以及酵素缺乏症患病率的上升，预计北美在预测期内将占据最大的市场份额。 先进的医疗基础设施的存在，如完善的医院、研究中心和製药公司，有助于酵素替代疗法（ERT）的开发和采用，是推动市场增长的主要因素之一。

复合年增长率最高的地区：

由于支持性监管框架、对遗传疾病的认识和诊断的提高以及有利的报销政策，预计欧洲在预测期内将呈现最高的复合年增长率。 完善的医疗保健系统和强大的基础设施能够对需要酵素替代疗法（ERT）的罕见疾病进行有效的诊断、治疗和管理，正在推动市场的增长。

主要进展：

2023 年6 月，BioMarin Pharmaceutical Inc. 宣布美国食品和药物管理局(FDA) 已批准对严重A 型血友病的诊断，其中在FDA 批准的药物中检测不到腺相关病毒血清型5 (AAV5) 抗体宣布批准 ROCTAVIAN□ (valoctocogene roxaparvovec-rvox) 基因疗法用于治疗成人。

2023 年 2 月，雀巢健康科学和 Codexis 宣布了 CDX-7108 治疗外分泌胰腺功能不全的 1 期临床试验的中期结果。 CDX-7108是一种脂肪酵素变体，专门设计用于克服现有胰酵素替代疗法（ERT）（PERT）的局限性。

报告内容

  • 区域和国家级细分市场的市场份额评估
  • 给新进入者的战略建议
  • 2021 年、2022 年、2023 年、2026 年和 2030 年的综合市场数据
  • 市场趋势（市场驱动因素/限制因素/机会/威胁/挑战/投资机会/建议）
  • 根据市场预测提出关键业务领域的战略建议
  • 竞争格局绘製主要共同趋势
  • 公司简介，包括详细的战略、财务状况和最新发展
  • 供应链趋势映射最新技术趋势

免费定制服务：

订阅此报告的客户将获得以下免费自定义选项之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要公司的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家/地区的市场估计/预测/复合年增长率（注：基于可行性检查）
  • 竞争基准测试
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概述
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究来源
    • 二手研究来源
    • 假设

第三章市场趋势分析

  • 驱动程序
  • 制约因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新冠肺炎 (COVID-19) 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间存在敌对关係

第 5 章全球酵素替代疗法 (ERT) 市场：按产品

  • 五倍子酵素
  • 贝拉葡萄糖酵素阿尔法
  • 拉罗尼酵素
  • 艾杜硫酵素
  • 伊米甘酵素
  • 阿加糖酵素β
  • 阿葡萄糖甘酵素α
  • 胰脂肪酵素
  • Erosulfacet Alpha
  • Asfotacepha
  • 其他产品

第 6 章全球酵素替代疗法 (ERT) 市场：按疾病分类

  • 胰腺外分泌功能不全 (EPI)
  • 庞贝病
  • 粘多醣贮积症
  • 戈谢病
  • 法布里病
  • 猎人病
  • 谢伊综合症
  • 马罗托-拉米综合征
  • 其他疾病

第 7 章全球酵素替代疗法 (ERT) 市场：按给药途径划分

  • 口头
  • 注射用
  • 其他给药途径

第 8 章全球酵素替代疗法 (ERT) 市场：按最终用户划分

  • 输液中心和家庭医疗保健环境
  • 医院
  • 诊所
  • 其他最终用户

第 9 章全球酵素替代疗法 (ERT) 市场：按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲地区

第 10 章主要进展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 推出新产品
  • 业务扩展
  • 其他关键策略

第 11 章公司简介

  • Takeda pharmaceutical Company Ltd.
  • Leadiant Biosciences Inc.
  • Biomarin Pharmaceuticals Inc.
  • Genzyme Corporation
  • Pfizer Inc.
  • Shire plc
  • Amicus Therapeutics
  • Sigma-Tau Pharmaceuticals, Inc.,
  • Essential Pharmaceuticals Limited
  • Merck KGa
  • AbbVie Inc
  • Sanofi Genzyme
  • Alexion Pharmaceuticals
  • Nestle Health Science
  • Astrazeneca Plc.
Product Code: SMRC23415

According to Stratistics MRC, the Global Enzyme Replacement Therapy Market is accounted for $10.1 billion in 2023 and is expected to reach $18.1 billion by 2030 growing at a CAGR of 8.6% during the forecast period. Enzyme replacement therapy (ERT) is carried out to replace a missing or deficient enzyme in a person with an inherited enzyme deficiency syndrome. Enzyme replacement therapy is a process in which different types of enzymes are administered in patients to overcome enzyme deficiencies or related malfunction. The rising prevalence of rare, chronic, and inherited disorders, including various kinds of lysosomal storage diseases and genetic disorders is fostering the demand for effective treatment options.

According to the Genetic and Rare Diseases Information Center (GARD), at present, there are around 25 to 35 million people in the United States that suffer from rare diseases.

Market Dynamics:

Driver:

Growing government spending on healthcare infrastructure

Governments of different nations are focusing on expanding the healthcare sector to treat people and combating health issues. Increasing initiatives by government and non-profit organizations in various countries to promote awareness among the general population lead to a gradual rise in the diagnosis rate of rare diseases. As a result of rising investment in healthcare infrastructure, the market size of enzyme replacement therapy is expected to expand in the assessment period.

Restraint:

Lack of Awareness

Lack of awareness about enzyme replacement therapy among developing nations is slowing down the adoption rate of enzyme replacement therapy. Also, the deficiency of technology and adequate infrastructure is expected to hamper the market growth. However, the lack of skilled healthcare technicians for this therapy and inadequate reimbursement policies in emerging countries are some of the factors limiting the market growth.

Opportunity:

Technological advancements

Significant developments around biotechnology have produced increasingly sophisticated and specialised enzyme replacement treatments. Recombinant enzymes may now be produced with better qualities such higher stability, specificity, and half-life due to advancements in recombinant DNA technology. Further investigation into gene therapy and other cutting-edge therapeutic approaches has the potential to boost ERT's efficacy in the future.

Threat:

High cost of these treatments

Due to the intricate manufacturing procedures required, the need for specialised infrastructure, and the relatively limited patient populations affected by uncommon genetic illnesses, medications are sometimes costly. For individuals, healthcare systems, and insurance companies, this high cost may provide access difficulties. The high cost of medications may make them difficult to afford and reimburse. The cost of treatments is also made more expensive by their duration.

COVID-19 Impact:

The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the enzyme replacement therapy market. The continuous spread of the pandemic and the measures taken by the governments of various countries have affected, and could continue to affect, the businesses, including future disruptions to supply chain and the manufacture or shipment of drug substance and finished drug products. In addition, has resulted in decreased public mobility, as well as impacted the diagnostic industries. Several diagnostic procedures and therapies that are non-emergent were put on hold to prevent the transmission of the novel corona virus.

The oral segment is expected to be the largest during the forecast period:

The oral segment is estimated to have a lucrative growth, due to the increasing patient preference for oral administration as it is convenient and non-invasive method of drug delivery. Ease of self-administration that allow patients to take their medication at home without the need for healthcare professional assistance, growing R&D efforts to develop oral formulations of enzyme replacement therapies and the potential advantages such as improved bioavailability and stability of certain enzymes when administered orally further boost the growth rate of the oral segment in the global market.

The hospital segment is expected to have the highest CAGR during the forecast period:

The hospital segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the availability of advanced healthcare infrastructure, specialized medical personnel, and supportive facilities for administering enzyme replacement therapy. The growing number of collaborations between hospitals and pharmaceutical companies to ensure the availability and proper administration of enzyme replacement therapies and hospital-based clinical research and development activities further boost the growth rate of the hospital segment in the ERT market.

Region with Largest share:

North America is projected to hold the largest market share during the forecast period owing to the availability of infusion centers, increase in acceptance of newer therapies, and rise in prevalence of enzyme deficiency. The presence of advanced healthcare infrastructure, including well-established hospitals, research centers, and pharmaceutical companies that contribute to the development and adoption of enzyme replacement therapies is one of the major factors propelling the market growth.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to supportive regulatory frameworks, the growing awareness and diagnosis of genetic disorders and favorable reimbursement policies. The presence of well-developed healthcare systems and robust infrastructure in that enable efficient diagnosis, treatment, and management of rare diseases requiring enzyme replacement therapy drive the growth of the market.

Key players in the market

Some of the key players profiled in the Enzyme Replacement Therapy Market include Takeda pharmaceutical Company Ltd., Leadiant Biosciences Inc., Biomarin Pharmaceuticals Inc., Genzyme Corporation, Pfizer Inc., Shire plc, Amicus Therapeutics, Sigma-Tau Pharmaceuticals, Inc., Essential Pharmaceuticals Limited, Merck KGa, AbbVie Inc, Sanofi Genzyme, Alexion Pharmaceuticals, Nestle Health Science and Astrazeneca Plc.

Key Developments:

In June 2023, BioMarin Pharmaceutical Inc. , announced that the United States Food and Drug Administration (FDA) approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.

In February 2023, Nestle Health Science and Codexis Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency. CDX-7108 is a lipase variant specifically engineered to overcome the limitations of existing pancreatic enzyme replacement therapy (PERT).

Products Covered:

  • Galsulfase
  • Velaglucerase Alfa
  • Laronidase
  • Idursulfase
  • Imiglucerase
  • Agalsidase Beta
  • Alglucosidasealfa
  • Pancrelipase
  • Elosulfasealfa
  • Asfotasealfa
  • Other Products

Diseases Covered:

  • Exocrine Pancreatic Insufficiency (EPI)
  • Pompe Disease
  • Mucopolysaccharidosis
  • Gaucher Disease
  • Fabry Disease
  • Hunter Disease
  • Scheie Syndrome
  • Maroteaux-Lamy Syndrome
  • Other Diseases

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Other Route of Administrations

End Users Covered:

  • Infusion Centers & Home Healthcare Setting
  • Hospitals
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Enzyme Replacement Therapy Market, By Product

  • 5.1 Introduction
  • 5.2 Galsulfase
  • 5.3 Velaglucerase Alfa
  • 5.4 Laronidase
  • 5.5 Idursulfase
  • 5.6 Imiglucerase
  • 5.7 Agalsidase Beta
  • 5.8 Alglucosidasealfa
  • 5.9 Pancrelipase
  • 5.10 Elosulfasealfa
  • 5.11 Asfotasealfa
  • 5.12 Other Products

6 Global Enzyme Replacement Therapy Market, By Disease

  • 6.1 Introduction
  • 6.2 Exocrine Pancreatic Insufficiency (EPI)
  • 6.3 Pompe Disease
  • 6.4 Mucopolysaccharidosis
  • 6.5 Gaucher Disease
  • 6.6 Fabry Disease
  • 6.7 Hunter Disease
  • 6.8 Scheie Syndrome
  • 6.9 Maroteaux-Lamy Syndrome
  • 6.10 Other Diseases

7 Global Enzyme Replacement Therapy Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Other Route of Administrations

8 Global Enzyme Replacement Therapy Market, By End User

  • 8.1 Introduction
  • 8.2 Infusion Centers & Home Healthcare Setting
  • 8.3 Hospitals
  • 8.4 Clinics
  • 8.5 Other End Users

9 Global Enzyme Replacement Therapy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Takeda pharmaceutical Company Ltd.
  • 11.2 Leadiant Biosciences Inc.
  • 11.3 Biomarin Pharmaceuticals Inc.
  • 11.4 Genzyme Corporation
  • 11.5 Pfizer Inc.
  • 11.6 Shire plc
  • 11.7 Amicus Therapeutics
  • 11.8 Sigma-Tau Pharmaceuticals, Inc.,
  • 11.9 Essential Pharmaceuticals Limited
  • 11.10 Merck KGa
  • 11.11 AbbVie Inc
  • 11.12 Sanofi Genzyme
  • 11.13 Alexion Pharmaceuticals
  • 11.14 Nestle Health Science
  • 11.15 Astrazeneca Plc.

List of Tables

  • Table 1 Global Enzyme Replacement Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Enzyme Replacement Therapy Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Enzyme Replacement Therapy Market Outlook, By Galsulfase (2021-2030) ($MN)
  • Table 4 Global Enzyme Replacement Therapy Market Outlook, By Velaglucerase Alfa (2021-2030) ($MN)
  • Table 5 Global Enzyme Replacement Therapy Market Outlook, By Laronidase (2021-2030) ($MN)
  • Table 6 Global Enzyme Replacement Therapy Market Outlook, By Idursulfase (2021-2030) ($MN)
  • Table 7 Global Enzyme Replacement Therapy Market Outlook, By Imiglucerase (2021-2030) ($MN)
  • Table 8 Global Enzyme Replacement Therapy Market Outlook, By Agalsidase Beta (2021-2030) ($MN)
  • Table 9 Global Enzyme Replacement Therapy Market Outlook, By Alglucosidasealfa (2021-2030) ($MN)
  • Table 10 Global Enzyme Replacement Therapy Market Outlook, By Pancrelipase (2021-2030) ($MN)
  • Table 11 Global Enzyme Replacement Therapy Market Outlook, By Elosulfasealfa (2021-2030) ($MN)
  • Table 12 Global Enzyme Replacement Therapy Market Outlook, By Asfotasealfa (2021-2030) ($MN)
  • Table 13 Global Enzyme Replacement Therapy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 14 Global Enzyme Replacement Therapy Market Outlook, By Disease (2021-2030) ($MN)
  • Table 15 Global Enzyme Replacement Therapy Market Outlook, By Exocrine Pancreatic Insufficiency (EPI) (2021-2030) ($MN)
  • Table 16 Global Enzyme Replacement Therapy Market Outlook, By Pompe Disease (2021-2030) ($MN)
  • Table 17 Global Enzyme Replacement Therapy Market Outlook, By Mucopolysaccharidosis (2021-2030) ($MN)
  • Table 18 Global Enzyme Replacement Therapy Market Outlook, By Gaucher Disease (2021-2030) ($MN)
  • Table 19 Global Enzyme Replacement Therapy Market Outlook, By Fabry Disease (2021-2030) ($MN)
  • Table 20 Global Enzyme Replacement Therapy Market Outlook, By Hunter Disease (2021-2030) ($MN)
  • Table 21 Global Enzyme Replacement Therapy Market Outlook, By Scheie Syndrome (2021-2030) ($MN)
  • Table 22 Global Enzyme Replacement Therapy Market Outlook, By Maroteaux-Lamy Syndrome (2021-2030) ($MN)
  • Table 23 Global Enzyme Replacement Therapy Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 24 Global Enzyme Replacement Therapy Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 25 Global Enzyme Replacement Therapy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 26 Global Enzyme Replacement Therapy Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 27 Global Enzyme Replacement Therapy Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 28 Global Enzyme Replacement Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global Enzyme Replacement Therapy Market Outlook, By Infusion Centers & Home Healthcare Setting (2021-2030) ($MN)
  • Table 30 Global Enzyme Replacement Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 31 Global Enzyme Replacement Therapy Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 32 Global Enzyme Replacement Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.